Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mander

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
BMJ Open|December 10, 2015
Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive studyLucy A Truman, Marcin L Pekalski, Paula Kareclas, et al.
Genetic Epidemiology|February 17, 2001
Association between the ancestral haplotype HLA A30B18DR3 and multiple sclerosis in central SardiniaP P Bitti, B S Murgia, A Ticca, et al.
The British Journal of Dermatology|October 14, 2024
A personalized and systematically designed adherence intervention improves photoprotection in adults with xeroderma pigmentosum (XP): results of the XPAND randomized controlled trialJessica Walburn, Sam Norton, Robert Sarkany, et al.
Lancet (London, England)|September 13, 2011
Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trialSusan A Jebb, Amy L Ahern, Ashley D Olson, et al.
Frontiers in Molecular Neuroscience|September 4, 2024
C286, an orally available retinoic acid receptor β agonist drug, regulates multiple pathways to achieve spinal cord injury repairMaria B Goncalves, Yue Wu, Earl Clarke, et al.
BMC Medicine|March 2, 2018
Adaptive designs in clinical trials: why use them, and how to run and report themPhilip Pallmann, Alun W Bedding, Babak Choodari-Oskooei, et al.
JCI Insight|October 5, 2018
The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetesEleonora Seelig, James Howlett, Linsey Porter, et al.
BMC Medicine|November 17, 2018
Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive designMunyaradzi Dimairo, Elizabeth Coates, Philip Pallmann, et al.
BMJ (Clinical Research Ed.)|June 20, 2020
The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive designMunyaradzi Dimairo, Philip Pallmann, James Wason, et al.
Trials|June 18, 2020
The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive designMunyaradzi Dimairo, Philip Pallmann, James Wason, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
BMJ Open|December 10, 2015
Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive studyLucy A Truman, Marcin L Pekalski, Paula Kareclas, et al.
Genetic Epidemiology|February 17, 2001
Association between the ancestral haplotype HLA A30B18DR3 and multiple sclerosis in central SardiniaP P Bitti, B S Murgia, A Ticca, et al.
The British Journal of Dermatology|October 14, 2024
A personalized and systematically designed adherence intervention improves photoprotection in adults with xeroderma pigmentosum (XP): results of the XPAND randomized controlled trialJessica Walburn, Sam Norton, Robert Sarkany, et al.
Lancet (London, England)|September 13, 2011
Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trialSusan A Jebb, Amy L Ahern, Ashley D Olson, et al.
Frontiers in Molecular Neuroscience|September 4, 2024
C286, an orally available retinoic acid receptor β agonist drug, regulates multiple pathways to achieve spinal cord injury repairMaria B Goncalves, Yue Wu, Earl Clarke, et al.
BMC Medicine|March 2, 2018
Adaptive designs in clinical trials: why use them, and how to run and report themPhilip Pallmann, Alun W Bedding, Babak Choodari-Oskooei, et al.
JCI Insight|October 5, 2018
The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetesEleonora Seelig, James Howlett, Linsey Porter, et al.
BMC Medicine|November 17, 2018
Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive designMunyaradzi Dimairo, Elizabeth Coates, Philip Pallmann, et al.
BMJ (Clinical Research Ed.)|June 20, 2020
The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive designMunyaradzi Dimairo, Philip Pallmann, James Wason, et al.
Trials|June 18, 2020
The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive designMunyaradzi Dimairo, Philip Pallmann, James Wason, et al.
Pageof 9